Vector Science and Therapeutics (TSXV:PAIN) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics LT-Debt-to-Total-Asset?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Vector Science and Therapeutics's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.00.

Vector Science and Therapeutics's long-term debt to total assets ratio stayed the same from Aug. 2024 (0.00) to Feb. 2026 (0.00).

Vector Science and Therapeutics  (TSXV:PAIN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Vector Science and Therapeutics LT-Debt-to-Total-Asset Related Terms

Vector Science and Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics LT-Debt-to-Total-Asset Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
LT-Debt-to-Total-Asset
0.00 0.00

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset 0.00 0.00 0.00 0.00 0.00
TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics LT-Debt-to-Total-Asset Calculation

Vector Science and Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2025 is calculated as

LT Debt to Total Assets (A: Aug. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2025 )/Total Assets (A: Aug. 2025 )
=0/4.146
=

Vector Science and Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=0/2.263
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Vector Science and Therapeutics (TSXV:PAIN) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vector Science and Therapeutics and its competitors.
Is Vector Science and Therapeutics' LT-Debt-to-Total-Asset too high?
Vector Science and Therapeutics' current LT-Debt-to-Total-Asset is 0.00. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' LT-Debt-to-Total-Asset compare to ABT and SYK?
Vector Science and Therapeutics' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Vector Science and Therapeutics and its competitors. Vector Science and Therapeutics's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price